Condition: HIV Infections · Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients treated with combination antiretroviral therapy will provide further insights into the long-term safety and durability of various antiretroviral therapeutic approached, the efficacy of HIV viral load and CD4 cell counts as predictors of disease progression and mortality, and the importance of adherence.
This description comes directly from the study's public registry record.
Anchalee Avihingsanon, MD, PhD · 66 2 2557334-5 · anchalee.a@hivnat.org
Stephen Kerr, PhD · 66 2 2557334-5 · s.kerr@unsw.edu.au
Always discuss trial participation with your own doctor first.
| HIV-NAT, Thai Red Cross AIDS Research Center | Bangkok, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00411983